Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genzyme, the rare disease arm of Sanofi, is paying Voyager Therapeutics $65 million up front as part of a pact to develop gene therapies for central nervous system disorders, including Parkinson’s disease, Friedreich’s ataxia, and Huntington’s disease. Genzyme, which gains an option to license multiple programs after proof-of-concept human studies, is also taking a stake worth $35 million in the Cambridge, Mass.-based biotech firm. Separately, Sanofi has eliminated about 100 R&D positions at its Boston research labs. The company calls the move a “natural evolution of its R&D organization.”
This article has been sent to the following recipient: